Skip to main content

Table 1 Body weight, body adiposity, lean body mass, and serum analysis

From: Sex-specific lipid molecular signatures in obesity-associated metabolic dysfunctions revealed by lipidomic characterization in ob/ob mouse

 

F

M

 

P values

Final BW (g)

47.6 ± 1.1

49.8 ± 0.7

 

ns

BW gain (g)

7.9 ± 0.8

8.1 ± 0.8

 

ns

Total body fat mass (g)

28.3 ± 0.5

26.1 ± 0.6

*

P < 0.05

Lean mass (g)

19.0 ± 0.4

20.3 ± 0.4

*

P < 0.05

% fat mass

57 ± 1

54 ± 1

**

P < 0.01

% lean mass

38 ± 1

42 ± 1

**

P < 0.01

Cumulative food intake (g)

1217 ± 1

1255 ± 1

 

ns

Food efficiency (g/ΔBW)

154 ± 12

155 ± 10

 

ns

Liver (%TF)

8.5 ± 0.3

11.5 ± 0.2

***

P < 0.001

VAT (%TF)

27.1 ± 0.5

29.3 ± 0.6

*

P < 0.05

SAT (%TF)

20.8 ± 0.3

17.0 ± 0.9

**

P < 0.01

SAT/VAT

0.77 ± 0.02

0.58 ± 0.03

***

P < 0.001

Serum analysis

 Fasted glucose (mM)

10.7 ± 0.3

9.1 ± 0.4

 

ns

 Fasted insulin (ng/ml)

2.1 ± 0.2

3.4 ± 0.4

*

P < 0.05

 HOMA-IR

0.8 ± 0.1

1.3 ± 0.1

**

P < 0.01

 Triglycerides (mM)

0.20 ± 0.01

0.65 ± 0.09

**

P < 0.01

 Adiponectin (pg/ml)

5740 ± 361

4985 ± 212

 

P = 0.06

 Resistin (pg/ml)

22.6 ± 2.9

44.6 ± 2.4

**

P < 0.01

 FGF21 (pg/ml)

5380 ± 189

3583 ± 444

**

P < 0.01

 TNFα (pg/ml)

465 ± 72

374 ± 55

 

ns

 IL1β (pg/ml)

88 ± 17

94 ± 16

 

ns

 IL6 (pg/ml)

29 ± 7

21 ± 3

 

ns

 IL10 (pg/ml)

437 ± 83

239 ± 28

*

P = 0.01

  1. Data are presented as mean ± sem, n = 7–10. Differences between sexes were determined by two-tailed student’s t test with statistical significance determined using the Holm-Sidak method, with alpha = 5.000%. Each row was analyzed individually, without assuming a consistent SD. *, P < 0.05, **, P < 0.01, ***, P < 0.001 M vs F were considered significant. ns = not significant. M male, F female, TF total fat, VAT visceral fat (comprises the gAT, omental and retroperitoneal adipose depots), SAT subcutaneous adipose tissue (comprises the iAT and dorsal adipose depots), HOMA-IR homeostatic model assessment-insulin resistance, FGF21 fibroblast growth factor 21, TNF tumor necrosis factor and IL interleukin